Relmada Therapeutics Inc. (RLMD)
RLMD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | RLMD on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001553643 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials
No annual revenue filed since the period ending 2013-08-31.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $5.7M cash; operating cash flow -$13.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 106,694,846 (2026-11-10); 73,333,622 a year earlier; 30,099,203 three years earlier. | Cover page 2026-11-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 1 424B5 takedowns | Latest 2026-01-30 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., Houston, Texas, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-05-12 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $4.0M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$13.9M | -$12.6M | $5.7M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$12.9M | -$9.6M | $11.3M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$19.1M | -$15.1M | $9.8M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | Not filed | -$19.9M | -$14.6M | $3.5M | No debt tags | Needs four quarters | 10-K 2026-03-19 |
| Q3 2025 2025-09-30 | Not filed | -$10.1M | -$6.7M | $1.4M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$9.9M | -$6.4M | $1.4M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2025 2025-03-31 | Not filed | -$17.6M | -$18.1M | $1.1M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | Not filed | -$18.7M | -$8.8M | $3.9M | No debt tags | Needs four quarters | 10-K 2026-03-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | S-3ASR | 2026-05-13 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-19 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-12 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-16 |
| Latest proxy DEFINITIVE ADDITIONAL MATERIALS | DEFA14A | 2026-04-17 |
Source: SEC EDGAR submissions feed, 610 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +7.9% |
| 1 month | +25.3% |
| 3 months | -11.4% |
| Year to date | -12.8% |
| 1 year | +8.5% |
| From 52-week high | -46.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CRMD | CorMedix Inc. | $4.82 | +3.43% | $383.4M |
| IRD | Opus Genetics Inc. | $4.04 | +1.51% | $390.5M |
| CTNM | Contineum Therapeutics Inc. | $9.67 | -1.93% | $379.7M |
| PBYI | Puma Biotechnology Inc | $7.34 | -5.53% | $379.5M |
| PEPG | PepGen Inc. | $4.19 | -3.90% | $395.0M |
| PRTA | Prothena Corporation plc | $7.97 | -2.33% | $409.3M |
| SPRY | ARS Pharmaceuticals Inc. | $3.59 | -7.71% | $360.9M |
| ASPE | Aspen Neuroscience Inc. | $12.23 | -2.86% | $355.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier